Stockreport

Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

STEMLINE THERAPEUTICS  (STML) 
Last stemline therapeutics earnings: 3/13 04:45 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.stemline.com/investor-relations
PDF NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and co [Read more]